Immunocore Holdings plc (NASDAQ:IMCR) Stock Position Lifted by Assetmark Inc.

Assetmark Inc. increased its position in Immunocore Holdings plc (NASDAQ:IMCR) by 6.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,555 shares of the company’s stock after buying an additional 1,878 shares during the quarter. Assetmark Inc. owned about 0.06% of Immunocore worth $951,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of IMCR. Exchange Traded Concepts LLC lifted its holdings in shares of Immunocore by 40.4% during the third quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock valued at $158,000 after purchasing an additional 1,461 shares during the last quarter. Tidal Investments LLC acquired a new position in Immunocore during the first quarter valued at $423,000. Nan Fung Group Holdings Ltd acquired a new position in Immunocore during the first quarter valued at $439,000. Connective Portfolio Management LLC acquired a new position in Immunocore during the third quarter valued at $218,000. Finally, DNB Asset Management AS raised its position in Immunocore by 35.0% during the second quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock valued at $244,000 after buying an additional 1,868 shares during the period. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore Stock Performance

Shares of Immunocore stock opened at $31.59 on Friday. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of -33.25 and a beta of 0.72. The stock’s 50-day moving average is $32.44 and its 200-day moving average is $38.66. Immunocore Holdings plc has a one year low of $29.72 and a one year high of $76.98. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76.

Immunocore (NASDAQ:IMCR) last released its earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.50. The business had revenue of $80.25 million for the quarter, compared to the consensus estimate of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. Immunocore’s quarterly revenue was up 23.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.59) earnings per share. Equities analysts predict that Immunocore Holdings plc will post -0.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on IMCR. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research report on Thursday, October 24th. Barclays decreased their target price on Immunocore from $92.00 to $66.00 and set an “overweight” rating for the company in a research note on Friday, August 9th. Oppenheimer restated an “outperform” rating and set a $89.00 target price (up previously from $87.00) on shares of Immunocore in a research note on Friday, August 9th. UBS Group initiated coverage on Immunocore in a research report on Thursday, October 24th. They set a “sell” rating and a $24.00 target price for the company. Finally, Needham & Company LLC dropped their price target on Immunocore from $78.00 to $71.00 and set a “buy” rating for the company in a report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $69.18.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.